Covered recipient · General Payments record
MARIO CASTRO
Allopathic & Osteopathic Physicians Internal Medicine Pulmonary Disease
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2019 · Entire year
$531,790.85
482 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2019 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $372,313.92 | 105 |
| Travel and Lodging | $77,021.22 | 202 |
| Consulting Fee | $73,124.50 | 19 |
| Food and Beverage | $9,331.21 | 156 |
By paying entity
PY2019 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | $193,364.71 | 186 |
| GENZYME CORPORATION | $123,046.66 | 97 |
| Regeneron Healthcare Solutions, Inc. | $112,341.78 | 111 |
| Teva Pharmaceuticals USA, Inc. | $40,879.14 | 43 |
| SANOFI-AVENTIS U.S. LLC | $25,652.25 | 10 |
| GlaxoSmithKline, LLC. | $25,296.02 | 25 |
| Genentech USA, Inc. | $5,772.34 | 6 |
| Novartis Pharmaceuticals Corporation | $3,196.00 | 2 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,180.00 | 1 |
| Regeneron Pharmaceuticals, Inc. | $61.95 | 1 |
Page 9 of 10; records 401–450 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
MARIO CASTRO
NPI 1881610004 · CMS profile ID 176181
Allopathic & Osteopathic Physicians / Internal Medicine / Pulmonary Disease
KANSAS CITY, KS
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 9 of 10; records 401–450 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=9#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- MARIO CASTRO, NPI 1881610004, CMS profile ID 176181. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 9 of 10; records 401–450 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=9#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- APA 7
- IndustryPayments. (2026). MARIO CASTRO, NPI 1881610004, CMS profile ID 176181. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 9 of 10; records 401–450 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=9#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
- Bluebook
- MARIO CASTRO, NPI 1881610004, CMS profile ID 176181, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 9 of 10; records 401–450 of 482 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1881610004?year=2019&recipient=provider&page=9#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2019
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30
482 matching records · $531,790.85 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 401–450 of 482.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| Regeneron Healthcare Solutions, Inc. | $283.86 | 02/15/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357485 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,300.00 | 02/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685353483 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,300.00 | 02/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685440203 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,758.50 | 02/14/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357483 | CMS |
| Regeneron Healthcare Solutions, Inc. | $125.00 | 02/13/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357481 | CMS |
| AstraZeneca Pharmaceuticals LP | $2,150.00 | 02/12/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685976107 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,758.50 | 02/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357475 | CMS |
| Regeneron Healthcare Solutions, Inc. | $6,437.00 | 02/11/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357477 | CMS |
| Regeneron Healthcare Solutions, Inc. | $427.50 | 02/11/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357479 | CMS |
| Regeneron Healthcare Solutions, Inc. | $165.96 | 02/08/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357469 | CMS |
| Regeneron Healthcare Solutions, Inc. | $117.91 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357471 | CMS |
| Regeneron Healthcare Solutions, Inc. | $37.07 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357473 | CMS |
| Teva Pharmaceuticals USA, Inc. | $57.48 | 02/08/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697862111 | CMS |
| Regeneron Healthcare Solutions, Inc. | $6,437.00 | 02/07/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357467 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685531947 | CMS |
| AstraZeneca Pharmaceuticals LP | $27.14 | 02/06/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685920631 | CMS |
| GlaxoSmithKline, LLC. | $16.37 | 02/06/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 671476139 | CMS |
| GENZYME CORPORATION | $121.36 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932791 | CMS |
| GENZYME CORPORATION | $2,759.00 | 02/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932793 | CMS |
| GENZYME CORPORATION | $14.95 | 02/05/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932795 | CMS |
| GENZYME CORPORATION | $6,130.00 | 02/05/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932797 | CMS |
| GENZYME CORPORATION | $502.89 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932799 | CMS |
| GENZYME CORPORATION | $959.79 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932801 | CMS |
| GENZYME CORPORATION | $7.00 | 02/05/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932803 | CMS |
| Regeneron Healthcare Solutions, Inc. | $2,758.50 | 02/04/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357463 | CMS |
| Regeneron Healthcare Solutions, Inc. | $225.00 | 02/04/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357465 | CMS |
| Regeneron Healthcare Solutions, Inc. | $24.99 | 02/03/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357461 | CMS |
| Regeneron Healthcare Solutions, Inc. | $226.62 | 02/01/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357459 | CMS |
| Teva Pharmaceuticals USA, Inc. | $214.38 | 01/31/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697675069 | CMS |
| Regeneron Healthcare Solutions, Inc. | $264.00 | 01/30/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357457 | CMS |
| AstraZeneca Pharmaceuticals LP | $109.43 | 01/29/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685411965 | CMS |
| AstraZeneca Pharmaceuticals LP | $10.44 | 01/29/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685466411 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $2,180.00 | 01/23/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 700443523 | CMS |
| GENZYME CORPORATION | $920.00 | 01/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 693932379 | CMS |
| Teva Pharmaceuticals USA, Inc. | $4,040.00 | 01/23/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697862103 | CMS |
| Regeneron Healthcare Solutions, Inc. | $340.57 | 01/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 673357455 | CMS |
| Teva Pharmaceuticals USA, Inc. | $115.78 | 01/22/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697679875 | CMS |
| Teva Pharmaceuticals USA, Inc. | $378.00 | 01/22/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 697862107 | CMS |
| AstraZeneca Pharmaceuticals LP | $23.20 | 01/17/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685117793 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,750.00 | 01/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685338909 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,000.00 | 01/17/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685356315 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,300.00 | 01/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685412213 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,600.00 | 01/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685638197 | CMS |
| AstraZeneca Pharmaceuticals LP | $29.00 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685683169 | CMS |
| AstraZeneca Pharmaceuticals LP | $4,000.00 | 01/17/2019 | Consulting Fee | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685767159 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 01/17/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685835553 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,600.00 | 01/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685923213 | CMS |
| AstraZeneca Pharmaceuticals LP | $3,750.00 | 01/17/2019 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685947945 | CMS |
| AstraZeneca Pharmaceuticals LP | $125.00 | 01/16/2019 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685289287 | CMS |
| AstraZeneca Pharmaceuticals LP | $1,591.48 | 01/16/2019 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 685638839 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $11,500.00 | 27 |
| PY2025 | Principal investigator | $517,850.26 | 86 |
| PY2024 | Recipient | $7,250.00 | 21 |
| PY2024 | Principal investigator | $581,361.15 | 45 |
| PY2023 | Recipient | $3,500.00 | 7 |
| PY2023 | Principal investigator | $465,662.37 | 44 |
| PY2022 | Recipient | $14,711.51 | 31 |
| PY2022 | Principal investigator | $121,284.22 | 12 |
| PY2021 | Recipient | $9,000.00 | 22 |
| PY2021 | Principal investigator | $169,147.88 | 26 |
| PY2020 | Recipient | $15,274.16 | 25 |
| PY2020 | Principal investigator | $78,092.05 | 10 |
| PY2019 | Recipient | $22,226.52 | 55 |
| PY2019 | Principal investigator | $22,455.40 | 5 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
113 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.33 | 12/24/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184280258 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,586.31 | 12/19/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184278646 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $653.40 | 12/11/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046802 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $522.65 | 12/11/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046804 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $600.00 | 12/11/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046806 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 12/08/2025 | Non-covered Recipient Entity University Of Kansas Medical Center Research Institute Inc Kumc Research Institute | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226096778 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $3,950.75 | 12/01/2025 | Non-covered Recipient Entity KUMC RESEARCH INSTITUTE INC | THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T | No dispute reported | 06/30/2026 | 1192173477 |
| Principal investigator 1 | GlaxoSmithKline, LLC. | $15,650.00 | 12/01/2025 | Non-covered Recipient Entity KUMC RESEARCH INSTITUTE INC | THE IMAGINE STUDY: A PHASE 3B OPEN LABEL, SINGLE ARM STUDY TO ASSESS T | No dispute reported | 06/30/2026 | 1192173481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,135.92 | 11/27/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184266125 |
| Recipient | GENZYME CORPORATION | $250.00 | 11/26/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106704 |
| Recipient | GENZYME CORPORATION | $500.00 | 11/26/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106717 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,628.61 | 11/20/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046800 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.33 | 11/19/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184262643 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,550.00 | 11/04/2025 | Non-covered Recipient Entity University Of Kansas Medical Center Research Institute Inc Kumc Research Institute | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226096773 |
| Recipient | GENZYME CORPORATION | $1,250.00 | 10/27/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106675 |
| Recipient | GENZYME CORPORATION | $250.00 | 10/24/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106711 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $2,821.52 | 10/23/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046798 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.33 | 10/17/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184251393 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250313 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250315 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250317 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $91.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250319 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $91.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250321 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250323 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $91.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250325 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $158.00 | 10/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184250327 |
| Recipient | GENZYME CORPORATION | $250.00 | 10/14/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106669 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $522.65 | 10/14/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046796 |
| Principal investigator 1 | PFIZER INC. | $83.44 | 10/03/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute Inc | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228824203 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $522.65 | 09/25/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046794 |
| Principal investigator 1 | Galvanize Therapeutics, Inc | $15,567.45 | 09/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS SCHOOL OF MEDICINE | CS006 RHEOX PIVOTAL | No dispute reported | 06/30/2026 | 1238409125 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,544.60 | 09/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184237494 |
| Principal investigator 1 | PFIZER INC. | $1,750.00 | 09/11/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute Inc | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228834728 |
| Principal investigator 1 | PFIZER INC. | $21,042.00 | 08/22/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute Inc | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228842740 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,519.56 | 08/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184228861 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.33 | 08/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184228863 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $260.33 | 08/20/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184228865 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $1,778.89 | 08/19/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046792 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $13.92 | 08/11/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226108765 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $668.00 | 07/25/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220124 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $99.00 | 07/25/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220126 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,450.00 | 07/25/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220128 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $80.00 | 07/25/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184220130 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,276.75 | 07/24/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046790 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $5,735.00 | 07/22/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046788 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $6,243.02 | 07/18/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046786 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,400.00 | 07/14/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108741 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $29,460.74 | 07/11/2025 | Non-covered Recipient Entity KUMC RESEARCH INSTITUTE INC | Randomized, Double-blind, Placebo-controlled, Parallel Group, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants with Moderate to Very Severe Chronic Obstructive Pulmonary Disease COPD | No dispute reported | 06/30/2026 | 1185538320 |
| Recipient | GENZYME CORPORATION | $250.00 | 07/11/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106688 |
| Recipient | GENZYME CORPORATION | $500.00 | 07/11/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106809 |
| Principal investigator 1 | Galvanize Therapeutics, Inc | $2,212.59 | 07/09/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS SCHOOL OF MEDICINE | CS006 RHEOX PIVOTAL | No dispute reported | 06/30/2026 | 1238409097 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,010.00 | 07/07/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226108736 |
| Principal investigator 1 | PFIZER INC. | $1,245.00 | 07/03/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228844002 |
| Principal investigator 1 | PFIZER INC. | $275.00 | 07/03/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER | A PHASE 2 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED PARALLELGROUP DOSERANGING STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF PF07275315 IN ADULT PARTICIPANTS WITH INADEQUATELY CONTROLLED MODERATETOSEVERE ASTHMA | No dispute reported | 06/30/2026 | 1228844023 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $634.13 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212481 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $164.21 | 07/02/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212483 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,477.85 | 06/30/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184212167 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $770.32 | 06/27/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211737 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,847.56 | 06/27/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211907 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $3,135.92 | 06/27/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184211933 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 06/16/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108725 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/15/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106799 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/14/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106700 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/13/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106696 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/13/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106757 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/13/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106805 |
| Recipient | GENZYME CORPORATION | $500.00 | 06/12/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106748 |
| Recipient | GENZYME CORPORATION | $250.00 | 06/06/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106773 |
| Recipient | GENZYME CORPORATION | $500.00 | 05/20/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106786 |
| Recipient | GENZYME CORPORATION | $500.00 | 05/18/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106763 |
| Recipient | GENZYME CORPORATION | $250.00 | 05/18/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106792 |
| Recipient | GENZYME CORPORATION | $250.00 | 05/17/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106681 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,385.15 | 05/05/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226108706 |
| Principal investigator 1 | Galvanize Therapeutics, Inc | $3,851.02 | 04/29/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS SCHOOL OF MEDICINE | CS006 RHEOX PIVOTAL | No dispute reported | 06/30/2026 | 1238409067 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 04/28/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108710 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,647.26 | 04/28/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108716 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,679.41 | 04/25/2025 | Non-covered Recipient Entity KUMC RESEARCH INSTITUTE INC | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185538316 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $1,810.43 | 04/25/2025 | Non-covered Recipient Entity KUMC RESEARCH INSTITUTE INC | A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK) | No dispute reported | 06/30/2026 | 1185538328 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $3,992.98 | 04/24/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046784 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $974.00 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184188669 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $15,650.00 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184188671 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,000.00 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184188673 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,535.00 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184188675 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $2,350.00 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184188677 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,750.00 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184188679 |
| Principal investigator 1 | Regeneron Pharmaceuticals, Inc. | $1,202.00 | 04/23/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER RESEARCH INSTITUTE INC | AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA | No dispute reported | 06/30/2026 | 1184188681 |
| Recipient | GENZYME CORPORATION | $500.00 | 04/17/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106663 |
| Recipient | GENZYME CORPORATION | $500.00 | 04/16/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106779 |
| Recipient | GENZYME CORPORATION | $250.00 | 04/15/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106767 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $8,999.17 | 04/11/2025 | Non-covered Recipient Entity KUMC RESEARCH INSTITUTE INC | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185538326 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,550.00 | 04/02/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226108663 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $150.00 | 04/02/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108686 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $2,850.00 | 03/17/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108644 |
| Recipient | GENZYME CORPORATION | $250.00 | 03/12/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106729 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $66.75 | 03/06/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046782 |
| Recipient | GENZYME CORPORATION | $500.00 | 03/01/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106651 |
| Recipient | GENZYME CORPORATION | $250.00 | 03/01/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106742 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $31,425.34 | 02/28/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM | A Phase 4 Multicenter Randomized Double blind Parallel Group Placebo controlled Study to Evaluate the Effect of Benralizumab on Structural and Lung Function Changes in Severe Eosinophilic Asthmatics (CHINOOK) | No dispute reported | 06/30/2026 | 1185538330 |
| Recipient | GENZYME CORPORATION | $500.00 | 02/28/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106736 |
| Recipient | GENZYME CORPORATION | $250.00 | 02/27/2025 | Covered Recipient Physician | A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Patients With Persistent Asthma | No dispute reported | 06/30/2026 | 1226106657 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,200.84 | 02/24/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose Ranging Study to Assess the Efficacy, Safety, and Tolerability of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma | No dispute reported | 06/30/2026 | 1226108670 |
| Principal investigator 1 | Teva Pharmaceuticals USA, Inc. | $204.60 | 02/21/2025 | Non-covered Recipient Entity University of Kansas Medical Center Research Institute, Inc. | A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma | No dispute reported | 06/30/2026 | 1244046842 |
| Principal investigator 1 | Galvanize Therapeutics, Inc | $34,678.06 | 02/18/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS SCHOOL OF MEDICINE | CS006 RHEOX PIVOTAL | No dispute reported | 06/30/2026 | 1238409019 |
| Principal investigator 1 | Galvanize Therapeutics, Inc | $34,277.56 | 02/18/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS SCHOOL OF MEDICINE | CS006 RHEOX PIVOTAL | No dispute reported | 06/30/2026 | 1238409021 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $400.00 | 02/18/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108650 |
| Principal investigator 1 | AstraZeneca UK Limited | $30,546.32 | 02/14/2025 | Non-covered Recipient Entity DUKE UNIVERSITY | A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic Obstructive Pulmonary Disease COPD with a History of COPD Exacerbations OBERON | No dispute reported | 06/30/2026 | 1185538318 |
| Recipient | GENZYME CORPORATION | $1,250.00 | 02/10/2025 | Covered Recipient Physician | Randomized, Double Blind, Placebo Controlled Study to Evaluate the Effect of Dupilumab on Airway Inflammation Through Assessments of Lung Function, Mucus Plugging and Other Lung Imaging Parameters in Patients With Asthma | No dispute reported | 06/30/2026 | 1226106722 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $101,199.89 | 01/29/2025 | Non-covered Recipient Entity KUMC RESEARCH INSTITUTE INC | Levante A Phase 2b Randomised Double Blind Placebo Controlled Dose Range Finding Study to Assess Efficacy and Safety of Multiple Dose Levels of Inhaled AZD8630 | No dispute reported | 06/30/2026 | 1185538322 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $14,605.04 | 01/27/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108656 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $7,326.06 | 01/17/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM | A Multicenter, Randomized, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Phase 3 Study to Evaluate the Efficacy and Safety of Benralizumab 100 mg in Patients with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD) with a History of Frequent COPD Exacerbations and Elevated Peripheral Blood Eosinophils (RESOLUTE) | No dispute reported | 06/30/2026 | 1185538314 |
| Principal investigator 1 | AstraZeneca Pharmaceuticals LP | $36,455.32 | 01/15/2025 | Non-covered Recipient Entity UNIVERSITY OF KANSAS MEDICAL CENTER CYSTIC FIBROSIS PROGRAM | A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chronic Obstructive Pulmonary Disease (COPD) with a History of Exacerbations | No dispute reported | 06/30/2026 | 1185538312 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,400.00 | 01/13/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108693 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $5,400.00 | 01/06/2025 | Non-covered Recipient Entity University Of Kansas Hospital | A Phase 2a, Open-label, Two-part Study to Evaluate the Mechanism of Action of Itepekimab (Anti-IL-33 mAb) on Airway Inflammation in Patients With Chronic Obstructive Pulmonary Disease (COPD) | No dispute reported | 06/30/2026 | 1226108700 |